ALNY240719P165000
- 0.45
- 0.000.00%
Alnylam Pharmaceuticals Newsroom
Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $357
Alnylam Pharmaceuticals Analyst Ratings
JPMorgan Chase Raises Price Target on Alnylam Pharmaceuticals to $248 From $160
Alnylam Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $150 Price Target
Alnylam Pharmaceuticals Analyst Ratings
Stifel Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $295
TD Cowen Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $282
Alnylam Pharmaceuticals Are Trading Higher Amid Possible Continued Strength After the Company Yesterday Announced Topline Results From Its HELIOS-B Phase 3 Study of Vutrisiran. Also, Multiple Firms Raised Their Respective Price Targets on the Stock.
Alnylam Pharmaceuticals Analyst Ratings
RBC Raises Price Target on Alnylam Pharmaceuticals to $250 From $235, Keeps Outperform Rating
Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Raises Price Target to $250
HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $400 Price Target
BMO Capital Maintains Outperform on Alnylam Pharmaceuticals, Maintains $234 Price Target
Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Maintains $283 Price Target
Alnylam Pharmaceuticals Analyst Ratings
HC Wainwright Adjusts Price Target on Alnylam Pharmaceuticals to $400 From $395, Maintains Buy Rating
Alnylam Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $400
RBC Capital Sticks to Their Buy Rating for Alnylam Pharma (ALNY)